AXIM Biotechnologies Applauds FDA’s Recent COVID-19 Test Policies to Support Rapid Neutralizing Antibody Tests

by Kyle | Nov 18, 2021 | Press Release

SAN DIEGO, Nov. 18, 2021 (GLOBE NEWSWIRE) — AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” or “the Company”), an international healthcare solutions company targeting oncological, COVID-19 and Dry Eye Disease (DED) diagnostics, today applauds the FDA...

AXIM Biotechnologies Partners with Arizona State University to Determine Antibody Levels Against COVID-19

by Kyle | Nov 16, 2021 | Press Release

SAN DIEGO, Nov. 16, 2021 (GLOBE NEWSWIRE) — AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting COVID-19 diagnostics and oncological research, announced today that it has...

AXIM Biotechnologies’ Development of Rapid Test for COVID-19 Neutralizing Antibodies is Cited to Demonstrate over 90% Sensitivity and 100% Specificity

by Kyle | Nov 9, 2021 | Press Release

Publication in the Journal of Clinical Virology Highlights Effectiveness of the Rapid Test To Identifying Immunity Levels of Functional Antibodies, Preventing the Virus from Infecting Cells SAN DIEGO, Nov. 09, 2021 (GLOBE NEWSWIRE) — AXIM Biotechnologies, Inc...

AXIM Biotechnologies Appoints Clinical Research and DED Expert Dr. Michael E. Stern to its Medical Advisory Board

by Kyle | Nov 2, 2021 | Press Release

SAN DIEGO, Nov. 02, 2021 (GLOBE NEWSWIRE) — AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” or “the Company”), an international healthcare solutions company targeting oncological, COVID-19 and Dry Eye Disease (DED) diagnostics, today announced it has...

AXIM Biotechnologies Appoints Dry Eye Disease Expert and Accomplished Optometrist Dr. Kelly K. Nichols to its Medical Advisory Board

by Kyle | Oct 20, 2021 | Press Release

SAN DIEGO, Oct. 20, 2021 (GLOBE NEWSWIRE) — AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” or “the Company”), an international healthcare solutions company targeting oncological, COVID-19 and dry eye disease (DED) diagnostics, today announced it has...

AXIM® Biotechnologies Develops Next Generation of its Rapid Neutralizing Antibody Test for COVID-19

by Kyle | Oct 12, 2021 | Press Release

SAN DIEGO, Oct. 12, 2021 (GLOBE NEWSWIRE) — AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological, COVID-19 and dry eye disease (DED) diagnostics, today announced...